European Organisation for Research and Treatment of Cancer - EORTC — Biomedical Watch V2

Traitements7programmes

Essais3liés

Publications14liées

SourceDBlocale

Traitements

7

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
BIBX 1382RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BIBX 1382 in treating patients who have solid tumors.	Cancer	Phase 1	À vérifier	Austria, Belgium, Denmark, France, Germany, Netherlands, Norway, Switzerland, …	À vérifier
CHOP regimenRandomized phase III trial to compare the effectiveness of combination chemotherapy with or without monoclonal antibody therapy in treating patients who have previously untreated HIV-associated non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy plus monoclonal antibody therapy is more effective than combination chemotherapy alone in treating HIV-associated non-Hodgkin's lymphoma.	SEP	Phase 3	À vérifier	Australia, Belgium, Canada, Denmark, Egypt, France, Hungary, Italy, …	À vérifier
Doxorubicin HydrochlorideThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.	Cancer, SEP	Phase 3	À vérifier	Australia, Belgium, Canada, Denmark, Egypt, France, Hungary, Italy, …	À vérifier
indisulamRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of E7070 in treating patients who have stage IV melanoma.	Cancer	Phase 2	À vérifier	Austria, Belgium, France, Germany, Italy, Norway, Portugal, Switzerland, …	À vérifier
vincristine sulfateRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether chemotherapy is more effective with or without rituximab for relapsed non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying combination chemotherapy and rituximab to see how well they work compared to combination chemotherapy alone in treating patients with relapsed non-Hodgkin's lymphoma.	SEP	Phase 3	À vérifier	Australia, Belgium, Canada, Denmark, Egypt, France, Hungary, Italy, …	À vérifier
BIBX 1382RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BIBX 1382 in treating patients who have solid tumors.	Cancer	Phase 1	À vérifier	Austria, Belgium, Denmark, France, Germany, Netherlands, Norway, Switzerland, United Kingdom	À vérifier
indisulamRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of E7070 in treating patients who have stage IV melanoma.	Cancer	Phase 2	À vérifier	Austria, Belgium, France, Germany, Italy, Norway, Portugal, Switzerland, United Kingdom	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
Rituximab	SEP	Phase 3	NCT00004179	Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma	COMPLETED
indisulam	Cancer	Phase 2	NCT00014625	E7070 in Treating Patients With Stage IV Melanoma	COMPLETED
BIBX 1382	Cancer	Phase 1	NCT00003980	BIBX 1382 in Treating Patients With Solid Tumors	SUSPENDED

Publications

14

Molécule	Indication / population	Titre	Journal	Date
Doxorubicin Hydrochloride		A dual-response size-shrinkable drug delivery system capable of deep tumor penetration for the treatment of solid tumors.	Colloids and surfaces. B, Biointerfaces
Doxorubicin Hydrochloride		Emodin alleviates renal fibrosis by targeting the ALKBH1/mC axis to sustain TRPV4 expression and inhibit TGF-β1/Smad2/3 signaling.	Toxicology and applied pharmacology
BIBX 1382		EGFR signaling upregulates surface expression of the GluN2B-containing NMDA receptor and contributes to long-term potentiation in the hippocampus.	Neuroscience
indisulam		Assessing the Stability of Molecular Glues with Weighted Ensemble Simulations.	Journal of chemical theory and computation
indisulam		Targeting PRMT5 inhibitor-induced adaptation in pancreatic cancer with the RBM39 degrader indisulam.	Cancer research communications
Doxorubicin Hydrochloride		Integration of RNA-seq and scRNA-seq to investigate the role of cell cycle-related biomarkers in sepsis.	PloS one
Doxorubicin Hydrochloride		Key genetic biomarkers and therapeutic potential in multiple sclerosis: Insights from integrated bioinformatics and mendelian randomization.	Computational biology and chemistry
Doxorubicin Hydrochloride		Single cell and bulk transcriptomics reveal metabolic reprogramming biomarker signatures during extracorporeal membrane oxygenation for cardiogenic shock.	Scientific reports
indisulam		RNA-binding motif proteins as context-dependent regulators of tumor-immune crosstalk, genome stability, and therapeutic vulnerabilities in cancer.	Frontiers in immunology
indisulam		[Modality strategy in Eisai drug discovery: challenges toward next-generation therapeutics using proximity-inducing compound].	Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Doxorubicin Hydrochloride		Ensemble Machine Learning- and Deep Learning-Driven Identification and Validation of Sennidin B as a Novel Dipeptidyl Peptidase-4 Inhibitor.	International journal of molecular sciences
Doxorubicin Hydrochloride		Aptamer Circuit-Engineered Bio-Nanovesicles With Self-Promoted Tumor-Targeting Loop for Efficient Immunogenic Chemotherapy.	Small methods
BIBX 1382		AZD8055 enhances in vivo efficacy of afatinib in chordomas.	The Journal of pathology
BIBX 1382		Integration of 101 machine learning algorithm combinations to unveil m6A/m1A/m5C/m7G-associated prognostic signature in colorectal cancer.	Scientific reports